Eupraxia Pharmaceuticals Inc. Common Stock (EPRX NASDAQ) stock market data APIs
$8.529
-0.42(-4.9%)
as of February 20, 2026
Try our APIs with
free plan!
Eupraxia Pharmaceuticals Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. The company's proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. Its lead product candidates include EP-104IAR, which is in Phase III clinical trial for the treatment of unmet medical needs and pain relief for knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
Prev. Close
8.529
Open
8.1116
High
8.774
Low
8.0892
52 wk Range
2.68-9.32
Market Cap
436 M
Shares Outstanding
50 648 K
EPS
-0.19
Beta
1.501
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Eupraxia Pharmaceuticals Inc. Common Stock data using free add-ons & libraries
Get Eupraxia Pharmaceuticals Inc. Common Stock Fundamental Data
Eupraxia Pharmaceuticals Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -29 603 326
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Eupraxia Pharmaceuticals Inc. Common Stock Earnings data
$
19.99
/mo.
What’s included:
- Latest Release: 2025-11-04
- EPS/Forecast: -0.1755
Get Eupraxia Pharmaceuticals Inc. Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Eupraxia Pharmaceuticals Inc. Common Stock News
New
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option
VICTORIA, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company lev...
Eupraxia Pharmaceuticals stock falls after pricing $55M public offering
* Eupraxia Pharmaceuticals (EPRX [https://seekingalpha.com/symbol/EPRX]) priced [https://seekingalpha.com/pr/20405094-eupraxia-pharmaceuticals-announces-pricing-of-us-55-million-public-offering-of-...
Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants
VICTORIA, British Columbia, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company lev...
Eupraxia Pharmaceuticals Announces Positive Tissue Health Data From Its Ongoing RESOLVE Trial
(RTTNews) - Eupraxia Pharmaceuticals Inc. (EPRX), Thursday announced positive 12-week and 36-week tissue health data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the ...
Get Eupraxia Pharmaceuticals Inc. Common Stock fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
